EpiMmUne.com
Title
IDM, immunotherapy against cancer
Description
Our mission is to provide highly effective treatments that maintain quality of life. To date, more than 10,000 injections have been safely administered during the course of IDM clinical trials. We have demonstrated that our products have low toxicity and are well tolerated by patients.
IDM has 5 products in clinical development. The most advanced, Junovan™, has completed a Phase III clinical trial in osteosarcoma. Three products are in Phase II clinical trials to treat bladder cancer, melanoma, and lung cancer and one is in Phase I for treatment of colorectal cancer.
IDM has a major product development partnership with Sanofi-Aventis in cancer immunotherapy. Medarex and Sanofi-Aventis are corporate partners and shareholders of IDM since 1993 and 2001 respectively.
Languages
English
Additional Information
Related Domains
- Antigen
- Biopharmaceuticals
- Biotechnology And Pharmaceuticals
- Bladder Cancer
- Cancer Vaccine
- Cancerology
- Cell Therapy
- Clinical Trials
- Colorectal Cancer
- Cordeliers
- Dendritic Cell
- Dendritic Cells
- Horie
- Idm
- Immune System
- Immunotherapy
- Leukaemia
- Macrophage
- Macrophages
- Melanoma
- Oncology
- Orphan Drug
- Osteosarcoma
- Prostate Cancer
- Tumour
- Vaccines
- Biotechnology and Pharmaceuticals
- IDM